Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PolyPid Ltd. - Ordinary Shares (NQ:PYPD)

5.152 -0.038 (-0.72%)
Delayed Quote Updated: 11:59 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PolyPid Ltd. - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data ↗
PolyPid (NASDAQ:PYPD) is approaching a November 28 PDUFA date for D-PLEX100, its lead product candidate for preventing surgical site infections in patients undergoing colorectal surgery, Chief... 
Via MarketBeat
Topics Bonds
News headline image
PolyPid (PYPD) Q2 2026 Earnings Call Transcript ↗
FDA accepts D-PLEX100 application with Priority Review, setting November approval target. 
Via The Motley Fool
Topics Earnings
News headline image
PolyPid Q2 Earnings Call Highlights ↗
PolyPid (NASDAQ:PYPD) said its second-quarter 2026 was marked by the FDA’s acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering... 
Via MarketBeat
Topics Earnings
PolyPid Ltd (NASDAQ:PYPD) Reports Q4 2025 Results, Focus on D-PLEX₁₀₀ Partnership and Regulatory Progress ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
A Look Ahead: PolyPid's Earnings Forecast ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 12, 2025 ↗
 
Via Benzinga
News headline image
PolyPid (PYPD) Q1 2026 Earnings Transcript ↗
PolyPid (PYPD) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
PolyPid Q1 Earnings Call Highlights ↗
PolyPid (NASDAQ:PYPD) said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate... 
Via MarketBeat
Topics Earnings
News headline image
PolyPid (PYPD) Q4 2025 Earnings Call Transcript ↗
PolyPid (PYPD) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
PolyPid Soars 3.4% on Pivotal FDA Endorsement for D-PLEX100 NDA
Jerusalem, Israel – December 3, 2025 – PolyPid Ltd. (NASDAQ: PYPD) witnessed a significant surge in its stock price today, gaining 3.4% following the announcement of supportive feedback from the U.S.... 
Via MarketMinute
News headline image
Earnings Scheduled For November 13, 2024 ↗
 
Via Benzinga
News headline image
PolyPid's Earnings: A Preview ↗
 
Via Benzinga
An Overlooked Crisis in Hospitals Could Be Pharma’s Next Great Opportunity
Via AB Newswire
News headline image
These stocks are moving in today's pre-market session ↗
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cisco To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
PYPD Stock Earnings: PolyPid Beats EPS for Q2 2024 ↗
PYPD stock results show that PolyPid beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
POLYPID LTD (NASDAQ:PYPD) Reports Q2 2025 Results with Mixed Market Reaction Despite Positive Phase 3 D-PLEX₁₀₀ Data ↗
PolyPid reports Q2 2025 results with positive Phase 3 data for D-PLEX₁₀₀, but EPS miss and no revenue. Stock dips slightly pre-market. 
Via Chartmill
PolyPid’s Game-Changing 60-Day GLP-1 Platform Could Disrupt $100B Weight Loss Market
Via AB Newswire
News headline image
With Fresh Funding and Strong Phase 3 Data, PolyPid Advances Towards FDA Approval
Surgical infection prevention breakthrough demonstrates 58% infection reduction as company secures funding through regulatory approval (NASDAQ:PYPD)* 
Via News Direct
News headline image
These stocks have an unusual volume in today's session ↗
Volume analysis on 2025-06-10: stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial ↗
PolyPid's D-PLEX100 met all key endpoints in a Phase 3 trial, showing a 38% drop in infection or death after colorectal surgery vs. standard care. 
Via Benzinga
News headline image
Earnings Scheduled For August 13, 2025 ↗
 
Via Benzinga
News headline image
Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
News headline image
Earnings Scheduled For May 14, 2025 ↗
 
Via Benzinga
News headline image
PolyPid Ltd. to Present at the Q1 Investor Summit Virtual Conference on March 11th, 2025
Via ACCESS Newswire
News headline image
Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.